reading REDEFINE threads from 2024 and half of it aged badly
reading REDEFINE threads from 2024 and half of it aged badly. Making the case below, and I expect to lose some of it in the comments. Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor. The engineering problem was…
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
do not assume the dosing intuitions from the GLP-1 boards transfer